Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ketoreductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120843624A reveals high-efficiency biocatalytic synthesis. Achieves 99% conversion and ee value. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN114621985B reveals enzymatic synthesis breakthrough. Delivers high purity and supply chain reliability for global pharmaceutical intermediate procurement strategies.
Patent CN114621986B reveals enzymatic synthesis for optically pure Taxol side chains. Discover cost-effective, scalable manufacturing solutions for pharmaceutical intermediates.
Patent CN114634957B reveals enzymatic synthesis for 4AA. Offers cost reduction and supply chain reliability for API manufacturing partners.
Patent CN102978249A details a single-enzyme biocatalytic route for statin intermediates. Achieve >99% ee with simplified workup and reduced manufacturing costs.
Patent CN102925501A details a high-efficiency enzymatic route for statin intermediates, offering superior purity and scalable manufacturing capabilities for global supply chains.
Patent CN116731988B reveals high-purity pharmaceutical intermediates synthesis via engineered ketoreductase, ensuring supply chain reliability and cost reduction.
Patent CN105985990B details a green enzymatic route for phenylephrine intermediates using KRED and antioxidants, offering significant cost reduction in API manufacturing.
Patent CN104711299B reveals enzymatic adrenaline synthesis. High purity, lower cost, and scalable supply chain solutions for pharmaceutical intermediates manufacturing.
Patent CN118755682A reveals BsSDR10 mutants for tetrabenazine reduction. Discover cost-effective, high-selectivity biocatalytic solutions for chiral drug manufacturing.
Patent CN109957585B reveals a high-efficiency ketoreductase process for chiral alcohol intermediates, offering significant cost reduction and scalable supply chain solutions.
Patent CN114032258B reveals enzymatic route for L-butylphthalide intermediate. Offers high purity and cost efficiency for pharmaceutical supply chains.
Patent CN103122355A details a thermostable ketoreductase enabling high-purity chiral alcohol manufacturing with significant cost reduction and supply chain reliability.
Patent CN118516426A reveals enzymatic route for chiral intermediates. High purity, mild conditions, cost-effective for pharma supply chains.
Patent CN104498510A enables enzymatic synthesis of atorvastatin side chain with superior stereoselectivity and scalable fermentation processes for global supply chains.
Patent CN117625571A reveals high-tolerance ketoreductase for ezetimibe intermediate. Enhances purity and reduces manufacturing costs for pharmaceutical supply chains.
Patent CN110229796B details enzymatic synthesis for high-purity duloxetine intermediates. Offers cost reduction and supply chain reliability for pharma manufacturing.
Patent CN111500652A reveals a novel enzymatic dynamic kinetic resolution for florfenicol. Discover cost-effective, high-purity veterinary drug intermediate manufacturing solutions.
Patent CN115537405A reveals a novel ketoreductase mutant for high-purity (S)-1-(3-chlorophenyl)-1,3-propanediol production, offering significant cost reduction in API manufacturing.
Patent CN111575334B reveals a stable immobilized enzyme method for synthesizing chiral alcohols, offering significant cost reduction and supply reliability for API manufacturing.